Cost of illness of glaucoma: A critical and systematic review

PharmacoEconomics

Volumn 27, Issue 3, 2009, Pages 189-198

  Fiscella, Richard G ^a   Lee, Jeff ^b   Davis, Elizabeth J H ^b   Walt, John ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; COST OF ILLNESS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; ECONOMIC ASPECT; EUROPE; GLAUCOMA SURGERY; HUMAN; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT REFUSAL; UNITED STATES; VISUAL FIELD; VISUAL IMPAIRMENT;

CANADA; COST OF ILLNESS; EUROPE; GLAUCOMA; HUMANS; UNITED STATES;

EID: 64749093972     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927030-00002     Document Type: Review

References (33)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000 Oct; 130 (4): 429-40
2. Leske MC, Heijl A, Hyman L, et al. Factors for progression. and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004 Apr; 15 (2): 102-6
3. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998 Oct; 126 (4): 487-97
4. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998 Oct; 126 (4): 498-505
5. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-7
6. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patients management. A review. Drugs Aging 2005; 22: 315-21
7. Akobundu E, Ju J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24 (9): 869-90
8. Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 2002; 120: 804-11
9. Gieser DK, Williams RT, O'Connell W. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 2006; 15: 419-25
10. Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 2003; 12: 456-62
11. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006; 124: 12-9
12. Lee PP, Levin LA, Walt JG, et al. Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data. Ophthalmology 2007; 114: 1241-7
13. Rein DB, Zhan P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006; 124: 1754-60
14. Vicente C, Walker J, Buys Y, et al. Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada. Curr Med Res Opin 2004; 32: 1245-51
15. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13: 283-90
16. Koleva D, Motterlini N, Schiavone M, et al. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study. Ophthalmologica 2007; 221: 340-7
17. Lindblom B, Nordmann JP, Sellem E, et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 2006; 82: 73-83
18. Neymark N, Buchholz P, Honrubia F, et al. The costs of treating glaucoma with combinations of topical drugs in Spain. Eur J Ophthalmol 2008; 18: 52-9
19. Oostenbrink JB, Rutten-van Molken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in the Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999; 98: 285-99
20. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001; 10: 184-91
21. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational, long term study of resource utilization in Europe. Br J Ophthalmol 2005; 89: 1245-9
22. Kobelt-Nguyen G, Gerdtham UG, Aim A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998; 7: 95-104
23. Lee PP, Kelly SP, Mills RP, et al. Glaucoma in the United States and Europe: predicting costs and surgical, rates based upon stage of disease. J Glaucoma 2007; 16: 471-8
24. Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics 2007; 25 (4): 287-308
25. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-1.3
26. Goldberg LD. Disease management programs for glaucoma: has the vision become a reality? Dis Manage Health Outcomes 2007; 15 (4): 199-205
27. Nordmann JP, Lafuma A, Deschaseaus C, et al. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J Glaucoma 2005; 14: 463-9
28. Olthoff CM, Schouten JS, van de Borne BW, et al. Non-compliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology 2005; 112: 953-61
29. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141: S28-33
30. Lee PP, Walt JG, Chiang TH, et al. A gap analysis approach to assess patient persistence with glaucoma medication. Am J Ophthalmol 2007; 144: 520-4
31. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598-606
32. Tingey D, Bernard LM, Grima DT, et al. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Can J Ophthalmol 2005; 40 (2): 161-9
33. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533-40